Hopstem biotechnology will participate the 2024 BIO International Convention (referred to as "BIO 2024"), taking place in San Diego Convention Center, California, from June 3-6, 2024.
Dr. Jing Fan, the founder and CEO of Hopstem Biotechnology, will deliver a speech at this event, highlighting the company's latest clinical advancements and discussing trends in cutting-edge innovations and emerging industries. Additionally, we will engage in discussions with experts in CGT fields during the convention to explore the future of the biotechnology industry, foster collaboration, and seek potential partnership opportunities.
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
Hopstem hNPC01 Earns FDA RMAT Designation for Chronic Stroke Therapy
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
Hopstem Announces FDA Granted iPSC Therapy hNPC01 Injection Fast Track Designation, Accelerating Global Breakthrough in Treatment of Cerebral Neural Injury Diseases
R&D Center: Building 11,Heda Medicine Valley V, Qiantang Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,Heda Medicine Valley lll,
Qiantang Area, Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
